fda d.i.s.c.o.: olaparib for gbrcam her2-negative metastatic breast cancer
Published 3 months ago • 50 plays • Length 5:31Download video MP4
Download video MP3
Similar videos
-
7:01
fda d.i.s.c.o. burst edition: fda approvals of jaypirca (pirtobrutinib) for relapsed or refractor...
-
7:01
fda d.i.s.c.o. burst edition: fda approvals of enhertu (fam-trastuzumab deruxtecan-nxki) for unr...
-
4:31
fda d.i.s.c.o. burst edition: fda approval of verzenio (abemaciclib) with endocrine therapy for p...
-
2:46
dr. brufsky on the fda approval of olaparib in brca breast cancer
-
4:31
fda d.i.s.c.o. burst edition: fda approval of enhertu (fam-trastuzumab deruxtecan-nxki) for adult...
-
9:00
fda d.i.s.c.o.: two approvals for alk-positive non-small cell lung cancer
-
1:29
bracanalysis cdx approved by fda for metastatic breast cancer
-
3:24
'tumors just vanished': cancer patients now in remission after drug trial
-
10:55
stage 4 cancer cure with tablets? olaparib cancer drug - dm(aiims) - targeted therapy hindi 2023
-
34:18
facebook live: what to expect at a breast clinic? - october 2022
-
3:50
olaparib beneficial for brca-mutated her2-negative breast cancer
-
2:23
fda approves new drug for metastatic breast cancer
-
15:00
new fda-approved targeted drug for treatment-resistant, er positive her2 negative breast cancer
-
2:44
olympia: adjuvant olaparib in gbrcam, her2-negative, high-risk, early breast cancer
-
1:22
dr. pusztai on rationale for the i-spy 2 trial with durvalumab/olaparib combo in her2- breast cancer
-
3:31
fda d.i.s.c.o. burst edition: fda approval of enhertu (fam-trastuzumab deruxtecan-nxki) for unres...
-
3:26
new treatment on the horizon | parp inhibitor - olaparib
-
0:50
fda approves elacestrant (orserdu) for er-positive, her2-negative, esr1-mutated breast cancer
-
0:24
fda recommendations #short
-
8:29
fda approves first companion diagnostic for her2 low metastatic breast cancer
-
4:01
fda d.i.s.c.o. burst edition: fda approval of trodelvy (sacituzumab govitecan-hziy) for hr-positi...
-
1:40
dr. agarwal on the fda approval of olaparib in hrr-mutant mcrpc